Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
复制标题
伐昔洛韦用于预防肾移植后巨细胞病毒病。
DOI：
--
复制
发表时间：
1999
影响因子：
158.5
通讯作者：
I. Lee
中科院分区：
文献类型：
--
作者：
D. Lowance;H. Neumayer;C. Legendre;J. Squifflet;J. Kovařík;P. Brennan;D. Norman;R. Mendez;M. Keating;Gary L. Coggon;A. Crisp;I. Lee
背景
BACKGROUND
Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease.
METHODS
A total of 208 CMV-negative recipients of a kidney from a seropositive donor and 408 CMV-positive recipients were randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 days after transplantation, with the dose adjusted according to renal function. The primary end point was laboratory-confirmed CMV disease in the first six months after transplantation.
RESULTS
Treatment with valacyclovir reduced the incidence or delayed the onset of CMV disease in both the seronegative patients (P<0.001) and the seropositive patients (P=0.03). Among the seronegative patients, the incidence of CMV disease 90 days after transplantation was 45 percent among placebo recipients and 3 percent among valacyclovir recipients. Among the seropositive patients, the respective values were 6 percent and 0 percent. At six months, the incidence of CMV disease was 45 percent among seronegative recipients of placebo and 16 percent among seronegative recipients of valacyclovir; it was 6 percent among seropositive placebo recipients and 1 percent among seropositive valacyclovir recipients. At six months, the rate of biopsy-confirmed acute graft rejection in the seronegative group was 52 percent among placebo recipients and 26 percent among valacyclovir recipients (P=0.001). Treatment with valacyclovir also decreased the rates of CMV viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources. Hallucinations and confusion were more common with valacyclovir treatment, but these events were not severe or treatment-limiting. The rates of other adverse events were similar among the groups.
CONCLUSIONS
Prophylactic treatment with valacyclovir is a safe and effective way to prevent CMV disease after renal transplantation.
登录
查看更多内容
影响因子：
158.5
作者：
BALFOUR, HH;CHACE, BA;FRYD, DS
通讯作者：
FRYD, DS
更昔洛韦治疗尸体肾同种异体移植受者的侵袭性巨细胞病毒感染。
DOI：
10.1016/s0022-5347(17)36918-5
发表时间：
1992
期刊：
The Journal of urology
影响因子：
--
作者：
Jordan,ML;HrebinkoJr,RL;Dummer,JS;Hickey,DP;Shapiro,R;Vivas,CA;Simmons,RL;Starzl,TE;Hakala,TR
通讯作者：
Hakala,TR
巨细胞病毒感染：对三百二十例连续肾移植的定量前瞻性研究。
影响因子：
3.8
作者：
Marker,SC;Howard,RJ;Simmons,RL;Kalis,JM;Connelly,DP;Najarian,JS;BalfourJr,HH
通讯作者：
BalfourJr,HH
一项关于阿昔洛韦与更昔洛韦加人免疫球蛋白预防实体器官移植后巨细胞病毒感染的前瞻性随机研究。
影响因子：
6.2
作者：
Dunn,DL;Gillingham,KJ;Kramer,MA;Schmidt,WJ;Erice,A;BalfourJr,HH;Gores,PF;Gruessner,RW;Matas,AJ;Payne,WD
通讯作者：
Payne,WD
预防性更昔洛韦治疗可减少心脏移植后的真菌和巨细胞病毒感染。
影响因子：
6.2
作者：
Wagner,JA;Ross,H;Hunt,S;Gamberg,P;Valantine,H;Merigan,TC;Stinson,EB
通讯作者：
Stinson,EB